PMID- 33352183
OWN - NLM
STAT- MEDLINE
DCOM- 20210517
LR  - 20221207
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 893
DP  - 2021 Feb 15
TI  - The effects of glucagon-like peptide-1 receptor agonists on glycemic control and 
      anthropometric profiles among diabetic patients with non-alcoholic fatty liver 
      disease: A systematic review and meta-analysis of randomized controlled trials.
PG  - 173823
LID - S0014-2999(20)30928-6 [pii]
LID - 10.1016/j.ejphar.2020.173823 [doi]
AB  - This study was undertaken to assess the effects of glucagon-like peptide-1 
      receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic 
      control and anthropometric profiles to see if they are effective in treating 
      patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes 
      mellitus (T2DM). We searched PubMed, Embase, Scopus, Web of Science (WOS), and 
      Cochrane Library databases to identify all the randomized clinical trials (RCTs) 
      up to August 23, 2020. Heterogeneity of the included studies was evaluated using 
      Cochrane's Q test and the I(2) statistic. Moreover, a random-effects model was 
      used to pool the weighted mean differences (WMDs) and their 95% confidence 
      intervals (CIs). Nine articles (12 studies) comprising a total of 780 
      participants aged 40-56 were finally selected. GLP-1RAs intake significantly 
      reduced body mass index (BMI) (WMD -1.57, 95%CI; -2.74, -0.39), 
      waist-circumference (WC) (WMD -4.14, 95%CI; -7.09, -1.19), body weight (WMD 
      -4.20, 95%CI; -8.15, -0.25) among the body mass indices. Additionally, GLP-1RAs 
      leads to lower postprandial plasma glucose (PPG) levels (WMD -25.73 mg/dl, 95%CI; 
      -32.71, -18.75). We also found that GLP-1RAs intake has no significant effect on 
      the waist-hip ratio (WHR) (WMD -0.01, 95%CI; -0.03, 0.02), fasting blood glucose 
      (FBG) (WMD -2.12 mg/dl, 95%CI; -6.23, 1.96), hemoglobin A1c (HbA1c) (WMD -0.08%, 
      95%CI; -0.21, 0.04), and homeostatic model assessment for insulin resistance 
      (HOMA-IR) levels (WMD -0.31, 95%CI; -0.69, 0.07). GLP-1RAs therapy showed a 
      greater reduction in BMI, body weight, WC, and PPG, but not in WHR, HOMA-IR, FBG, 
      and HbA1c compared with other therapies in patients with T2DM and NAFLD.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Nowrouzi-Sohrabi, Peyman
AU  - Nowrouzi-Sohrabi P
AD  - Department of Biochemistry, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran; Student Research Committee, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Rezaei, Shahla
AU  - Rezaei S
AD  - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; 
      Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz 
      University of Medical Sciences, Shiraz, Iran.
FAU - Jalali, Mohammad
AU  - Jalali M
AD  - Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz 
      University of Medical Sciences, Shiraz, Iran.
FAU - Ashourpour, Mahkameh
AU  - Ashourpour M
AD  - Department of Nutrition Sciences, School of Health, Larestan University of 
      Medical Sciences, Larestan, Iran; Emam Reza Teaching Hospital, Larestan 
      University of Medical Sciences, Larestan, Iran.
FAU - Ahmadipour, Ahmad
AU  - Ahmadipour A
AD  - Pharmaceutics Research Center, Kerman University of Medical Sciences, Kerman, 
      Iran.
FAU - Keshavarz, Pedram
AU  - Keshavarz P
AD  - Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, 
      Iran; Department of Radiology, Tbilisi State Medical University (TUMS), Tbilisi, 
      Georgia.
FAU - Akbari, Hamed
AU  - Akbari H
AD  - Endocrinology and Metabolism Research Center, Institute of Basic and Clinical 
      Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran; 
      Department of Biochemistry, School of Medicine, Kerman University of Medical 
      Sciences, Kerman, Iran. Electronic address: hamedakbari6989@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201219
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adiposity/drug effects
MH  - Adult
MH  - Anthropometry
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy/epidemiology
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism
MH  - Glycated Hemoglobin/metabolism
MH  - *Glycemic Control/adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Incretins/adverse effects/*therapeutic use
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/blood/diagnosis/*drug therapy/epidemiology
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - Exenatide
OT  - Glucagon-like peptide-1 receptor agonist
OT  - Liraglutide
OT  - Non-alcoholic fatty liver disease
OT  - Type 2 diabetes mellitus
EDAT- 2020/12/23 06:00
MHDA- 2021/05/18 06:00
CRDT- 2020/12/22 20:08
PHST- 2020/10/28 00:00 [received]
PHST- 2020/12/14 00:00 [revised]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/05/18 06:00 [medline]
PHST- 2020/12/22 20:08 [entrez]
AID - S0014-2999(20)30928-6 [pii]
AID - 10.1016/j.ejphar.2020.173823 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2021 Feb 15;893:173823. doi: 10.1016/j.ejphar.2020.173823. Epub 
      2020 Dec 19.